NCT02549651 - MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2016

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

MEDI4736

MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion

DRUG

tremelimumab

Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion

DRUG

AZD9150

AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion

Trial Locations (13)

Research Site, Marseille

Research Site, Baltimore

Research Site, Durham

Research Site, Charleston

Research Site, Milwaukee

Research Site, Dallas

Research Site, Houston

Research Site, Albuquerque

Research Site, La Jolla

Research Site, Villejuif

Research Site, Dublin

Research Site, Galway

Research Site, Leicester